Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy
Nephrology Dialysis Transplantation · 2026
DOI: 10.1093/ndt/gfag001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Qinjie Weng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Autoantibodies, B-Lymphocytes, Immunoglobulin A. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Major International (Regional) Joint Research Program of National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis and a leading cause of end-stage renal disease for young adults. The key pathogenesis of IgAN involves overproduction of galactose-deficient IgA1 (Gd-IgA1) and anti-Gd-IgA1 antibodies, resulting in formation of circulating immune complexes that deposit in the glomerular mesangium. Consequently, emerging therapeutic strategies for IgAN aim to target and reduce aberrant Gd-IgA1 and its associated immune complexes. This disease-modifying approach confers benefits across multiple stages of IgAN progression, particularly in the early phase to halt irreversible renal damage. B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) are critical cytokines that promote the differentiation, development and activation of B cells and plasma cells. Telitacicept, a novel recombinant fusion protein that dual-targets BAFF and APRIL, exhibits considerable therapeutic potential by inhibiting the production of Gd-IgA1 and its autoantibodies. Stage A results of the Phase 3 clinical trial demonstrated that patients in the telitacicept group achieved a 55% reduction in 24-h urinary protein-to-creatinine ratio and stable estimated glomerular filtration rate at Week 39 versus the placebo group, with favorable tolerability and safety. This review summarizes current progresses in targeting Gd-IgA1-producing cells for the treatment of IgAN, with a focus on therapeutic strategies including BAFF/APRIL inhibitors. Furthermore, it delineates the major challenges and future research directions aimed at optimizing these interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
- Institute of Nephrology, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
ORCID-Profile: Qinjie Weng
Förderung
- National Key Research and Development Program of China
- Major International (Regional) Joint Research Program of National Natural Science Foundation of China
- National Natural Science Foundation of China
- Shanghai Shenkang Hospital Development Center
- National Facility for Translational Medicine (Shanghai) Open subjects
- Program of Shanghai Academic/Technology Research Leader
- Science and Technology Innovation Action Plan of Shanghai Science and Technology Committee
- Shanghai Municipal Education Commission
Zitieren
APA
Weng, Q., Zhu, X., Ren, H., Li, X., & Xie, J. (2026). Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag001
Vancouver
Weng Q, Zhu X, Ren H, Li X, Xie J. Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag001
BibTeX
@article{Weng2026,
author = {Weng, Qinjie and Zhu, Xinyi and Ren, Hong and Li, Xiao and Xie, Jingyuan},
title = {Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag001}
}
EUVIMED